Zymeworks Outlines Strategic Priorities and Outlook for 2024 and 2025 4-01-2024, 18:15

Invixium Acquires Triax Technologies to Expand its Biometric Solutions with AI-based RTLS Offering for Improved Safety and Productivity at Industrial Sites and Critical Infrastructure 17-07-2024, 21:33

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26